Latest Nebulizer Stories
NEW YORK, Nov.
Anesthesia Information Management Systems Market to See a Five Fold Increase VANCOUVER, Nov. 17 /PRNewswire/ - According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S.
MIDLOTHIAN, Va., Nov.
MONMOUTH JUNCTION, N.J., Oct. 19 /PRNewswire/ -- Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.
MIDLOTHIAN, Va., Oct. 1 /PRNewswire/ -- Today, PARI Respiratory Equipment introduced the PEP S, a device that provides positive expiratory pressure that can be used with all PARI LC reusable nebulizers.
MONTEREY, Calif., Sept. 23 /PRNewswire/ -- PARI Pharma's Altera, which uses eFlow Technology, is the first drug-specific nebuliser for cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston.
MONTEREY, Calif., Sept. 14 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma.
MONMOUTH JUNCTION, N.J., Sept. 14 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation).
NAPA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc.
SAN DIEGO, Sept. 10 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF).
- The act of sweetening by admixture of some saccharine substance.